THC

C3 Industries Launches Cannabis-Infused "Galactic Cannabis Gummies" in Massachusetts, Elevating Consumers' Experience to New Heights

Retrieved on: 
Thursday, March 21, 2024
ANN, High, Gummy candy, Relaxation, High Profile, C3, Euphoria, THC, Watermelon, Commonwealth, Drug

ANN ARBOR, Mich., March 21, 2024 /PRNewswire/ -- C3 Industries ("C3" or "the Company,") a leading multi-state cannabis company dedicated to crafting premium cannabis experiences for consumers, announced the launch of its fast-acting cannabis-infused gummies by Galactic Cannabis in the Massachusetts market.

Key Points: 
  • ANN ARBOR, Mich., March 21, 2024 /PRNewswire/ -- C3 Industries ("C3" or "the Company,") a leading multi-state cannabis company dedicated to crafting premium cannabis experiences for consumers, announced the launch of its fast-acting cannabis-infused gummies by Galactic Cannabis in the Massachusetts market.
  • Building upon the success of the Company's previous cannabis product rollouts, including flower, pre-rolls, vapes and concentrates, C3 Industries' Galactic Cannabis gummies offer consumers a delightful and convenient way to embark on a cosmic journey.
  • C3 Industries VP of Marketing, Scott Franco said, "We're excited to offer our new edibles line to the consumers of Massachusetts.
  • For the Massachusetts market, the launch of Galactic Cannabis gummies signifies more than just the introduction of another cannabis product.

CBD Oracle Lab Study Finds "Hemp Gummies" Sold on Amazon with Huge Doses of Delta-8 THC

Retrieved on: 
Wednesday, March 20, 2024
Future, CBD, EBay, Walmart, THC, Policy, Oracle, Doctor of Philosophy, Online shopping

TUSTIN, Calif., March 20, 2024 /PRNewswire/ -- A lab analysis commissioned by CBD Oracle, a cannabis consumer research company, has identified products available on Amazon containing huge quantities of delta-8 THC, which is banned in many states. Despite this, a recent survey revealed that the intoxicating cannabinoid is still popular with teens.

Key Points: 
  • TUSTIN, Calif., March 20, 2024 /PRNewswire/ -- A lab analysis commissioned by CBD Oracle , a cannabis consumer research company, has identified products available on Amazon containing huge quantities of delta-8 THC, which is banned in many states.
  • CBD Oracle purchased 56 hemp products from popular brands on Amazon, sending a selection of gummies, tinctures, topical creams and mints to InfiniteCAL for analysis.
  • Amazon policy prohibits CBD and THC, but brands advertise large doses of unnamed "hemp" ingredients while listing benefits associated with CBD, such as promoting "calm" and "restful nights."
  • They might not contain an ingredient banned by Amazon, but the lab results reveal an even bigger scam: they are just overpriced gummy bears.

Curaleaf to Acquire Northern Green Canada to Bolster European Flower Supply

Retrieved on: 
Tuesday, March 19, 2024
Certification, Establishment, Acquisition, NGC, GMP, Cannabis, TSX, GACP, THC, Drug

NEW YORK, March 19, 2024 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced it has signed a deal to acquire Northern Green Canada ("NGC"), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. NGC also partners with Canadian GACP cultivators to produce and distribute finished cannabis products to both the domestic and global markets.

Key Points: 
  • NGC also partners with Canadian GACP cultivators to produce and distribute finished cannabis products to both the domestic and global markets.
  • By integrating NGC, Curaleaf can significantly increase its European margins while extending its global footprint across three continents: North America, Europe, and Australasia (Australia/New Zealand).
  • It allows Curaleaf to safeguard our position in Europe, enhancing our supply chain while increasing our margins.
  • Lisa McCormack, President and CEO of Northern Green Canada, said, "The NGC team is excited to become a part of the Curaleaf family.

Curaleaf to Acquire Northern Green Canada to Bolster European Flower Supply

Retrieved on: 
Tuesday, March 19, 2024
Certification, Establishment, Acquisition, NGC, GMP, Cannabis, TSX, GACP, THC, Drug

NEW YORK, March 19, 2024 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced it has signed a deal to acquire Northern Green Canada ("NGC"), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. NGC also partners with Canadian GACP cultivators to produce and distribute finished cannabis products to both the domestic and global markets.

Key Points: 
  • NGC also partners with Canadian GACP cultivators to produce and distribute finished cannabis products to both the domestic and global markets.
  • By integrating NGC, Curaleaf can significantly increase its European margins while extending its global footprint across three continents: North America, Europe, and Australasia (Australia/New Zealand).
  • It allows Curaleaf to safeguard our position in Europe, enhancing our supply chain while increasing our margins.
  • Lisa McCormack, President and CEO of Northern Green Canada, said, "The NGC team is excited to become a part of the Curaleaf family.

Real Isolates and Sanctuary Medicinals Announce Launch of Smokenol™-Infused Product Lines

Retrieved on: 
Tuesday, March 12, 2024
Temperature, Cannabinoid, Science, Partnership, Patient, Research, Smoke, Smoking, Medicinals, THC, Sanctuary, Medicinal plants

WOBURN, Mass., March 12, 2024 /PRNewswire/ -- Sanctuary Medicinals is pleased to announce an exciting new partnership with Real Isolates, utilizing their patented Smokenol™ cannabis smoke extraction process for infusion in select Sanctuary products.

Key Points: 
  • WOBURN, Mass., March 12, 2024 /PRNewswire/ -- Sanctuary Medicinals is pleased to announce an exciting new partnership with Real Isolates, utilizing their patented Smokenol™ cannabis smoke extraction process for infusion in select Sanctuary products.
  • Partnering with Real Isolates is a perfect example of that commitment.
  • Co-Founder of Real Isolates, Andy Westerkamp, explains "Real Isolates and Sanctuary Medicinals prioritize quality of life for patients and consumers.
  • Alex Hildrith, Laboratory Director for Sanctuary adds, "Sanctuary's lab team is very excited to announce our official partnership with Real Isolates.

InvestmentPitch Media Video Discusses StickIt Technologies and its Portfolio of Products Bringing New Enhanced Experiences to Consumers Smoking or Drinking Various Products

Retrieved on: 
Tuesday, March 12, 2024
Smoking, News, Cannabinoid, Terpene, Drinking, CBG, THC, Cannabis, Research, Drug

Vancouver, British Columbia--(Newsfile Corp. - March 12, 2024) - InvestmentPitch Media video features StickIt Technologies (CSE: STKT), a company at the forefront of the global cannabis industry with a portfolio of revolutionary products that bring new enhanced experiences to consumers smoking or drinking various products.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - March 12, 2024) - InvestmentPitch Media video features StickIt Technologies (CSE: STKT), a company at the forefront of the global cannabis industry with a portfolio of revolutionary products that bring new enhanced experiences to consumers smoking or drinking various products.
  • For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company.
  • SipIt, another new product, is a special straw containing a hidden cartridge containing cannabinoids such as THC and CBD.
  • For more information, please visit the company's website www.stickit-labs.com , contact Eli Ben-Haroosh, CEO, by email at [email protected] .

RETRANSMISSION: Akanda Corp. Signs Share Purchase and Escrow Agreements for the Sale of Portuguese Assets to Somai Pharmaceuticals

Retrieved on: 
Friday, March 1, 2024
CBPM, USD, Amend, Sale, RPK, Medicine, LDA, Patient, CBD, THC, Akanda, Schedule 2, Resolution

This strategic move underscores both companies' commitment to advancing the medical cannabis industry and enhancing patient access to high-quality cannabis treatments.

Key Points: 
  • This strategic move underscores both companies' commitment to advancing the medical cannabis industry and enhancing patient access to high-quality cannabis treatments.
  • Under the terms of the Share Purchase Agreement, Somai will acquire RPK, Akanda's indirect Portuguese subsidiary, for a total consideration of Two Million United States Dollars (USD $2,000,000).
  • The execution of the Share Purchase Agreement and Escrow Agreement follows the Amended Non-Binding Letter of Intent ("LOI") announced on February 1, 2024, and represents a crucial step towards the transaction's completion.
  • The closing of the proposed sale is subject to customary due diligence, representations, warranties, covenants, indemnities, and other closing conditions.

Can B Corp. Secures Ownership and Control of Two Cannabis Patents Valued at $122 Million and Potentially in Excess of $750 Million

Retrieved on: 
Monday, March 11, 2024
OTCQB, Cancer, Anxiety, THCA, Shikimate pathway, Growth, CBN, Cannabinoid, European, Health, Ground substance, Chronic pain, Patent, Federal court, THC, PTSD, Cannabis, Sleep, IBS, Controlled Substances Act, Pharmaceutical industry

HICKSVILLE, NY, March 11, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Can B Corp., a Florida corporation (OTCQB: CANB) (“Can B”), a health and wellness company specializing in developing, producing and selling hemp-derived cannabinoid products, is pleased to announce that it has secured ownership and control of two cannabis patents that were valued at $122 million, applying a 90% discount and assuming a revenue stream through August 2034, and further based on only CBD claims and only in the U.S. It is believed that if the global THC and CBD markets were added to the valuation, then the value of the patents is potentially up to $750 million.

Key Points: 
  • It is believed that if the global THC and CBD markets were added to the valuation, then the value of the patents is potentially up to $750 million.
  • These patents were previously awarded to United Cannabis Corporation and recently assigned to Can B by a court procedure.
  • The patents were valued at $122 million in December 2020 by an independent third-party valuation team, which used a 90% discount rate due to the emerging nature of the industry.
  • We believe there is a strong opportunity to monetize these patents as they represent important innovations in this industry.

Evn Introduces a Game-Changer in Cannabis Edibles with New Hemp-Derived Live Resin Gummies

Retrieved on: 
Friday, March 8, 2024
Health, Hemp, Cannabis, CBD, THC, Drug

Live resin , the star ingredient in Evn's new product, is renowned for its superior quality and purity.

Key Points: 
  • Live resin , the star ingredient in Evn's new product, is renowned for its superior quality and purity.
  • Unlike traditional extracts, live resin captures a fuller profile of the cannabis plant's compounds, including its all of its flavors and aromas.
  • "We are incredibly proud to introduce our Live Resin Gummies to the market," stated CEO Josh Krumholz.
  • Evn's Hemp-derived Live Resin Gummies distinguish themselves from competitors through several unique selling points:
    The use of live resin, which provides a fresher and richer cannabis experience.

Brains Bioceutical Corp, the Global Leader in Natural Cannabinoid APIs, Introduces Revolutionary Solid THC, Ushering in a New Era of Clinical Research

Retrieved on: 
Tuesday, March 5, 2024
Mental health, Active ingredient, USD, API, Quality of life, Drug development, Hope, Pharmacy, Safety, Pain management, JCAC, D9, Health, Patient, THC, Medicine, Veteran, DSM-IV codes, Cannabis, Face

This milestone reflects the company's commitment to innovation and its position at the forefront of the cannabinoid pharmaceutical industry.

Key Points: 
  • This milestone reflects the company's commitment to innovation and its position at the forefront of the cannabinoid pharmaceutical industry.
  • This breakthrough not only signifies a significant advancement in cannabinoid research but also underscores our commitment to driving innovation in pharmaceuticals.” Ricky Brar CEO & Chairman of Brains Bio.
  • "As a scientist deeply involved in cannabinoid research, I am thrilled by Brains Bio announcement of the solid D9 THC API.
  • The solid D9 THC is not just a product; it’s a symbol of Brains Bio commitment to pioneering the future of healthcare and pharmaceuticals.